Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), By Biomarker (Alpha-fetoprotein, Neuron-specific enolase), By End Use, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Pediatric Allergy Diagnostics Market Growth & Trends
The global pediatric allergy diagnostics market is anticipated to reach USD 4.68 billion by 2030 and is projected to grow at a CAGR of 10.1% during the forecast period, according to a new report by Grand View Research, Inc., driven by the increasing prevalence of allergic conditions among children worldwide. Allergies, including asthma, rhinitis, and food allergies, have become a major public health concern, especially in developed countries. A report published by the World Allergy Organization Journal in October 2023 highlighted that the lifetime prevalence rate of rhinitis symptoms in children was 18.7%. In addition, 14.3% of children experienced rhinitis symptoms within the past 12 months.
Furthermore, 5.6% of children reported having current symptoms of rhinoconjunctivitis. The rising incidence is largely attributed to environmental changes, dietary shifts, and increased awareness of allergic conditions. As a result, the demand for accurate and early diagnosis has surged, expanding the market. This market encompasses various diagnostic tools and tests, such as skin prick tests, specific IgE tests, and in vitro assays, which are crucial for identifying allergic triggers in children. The market's growth is further fueled by advancements in diagnostic technologies, improving the accuracy and ease of allergy testing, making it a pivotal segment in pediatric healthcare.
Technological advancements in diagnostic tools are a crucial factor driving the market's growth. Traditional methods, such as skin prick tests and specific IgE blood tests, have been the standard for diagnosing allergies. However, these methods can be uncomfortable for children and may not always provide the most accurate results. The market is shifting towards more sophisticated technologies, including molecular diagnostics and multiplex assays. These innovations offer higher sensitivity and specificity, allowing for the detection of multiple allergens simultaneously from a single sample. Moreover, advancements in non-invasive testing methods, such as saliva-based diagnostics, make the testing process more child-friendly, encouraging widespread adoption in pediatric settings. As these technologies continue to evolve, they are expected to drive significant growth in the market by improving diagnostic accuracy and patient compliance.
In addition, with the rising prevalence of allergic conditions such as asthma, food allergies, and atopic dermatitis in children, there is a heightened focus on early diagnosis and management. Awareness campaigns led by healthcare organizations, schools, and governments are educating parents and caregivers about the signs and symptoms of allergies, the importance of early detection, and the potential long-term impacts of untreated allergies. One such initiative is the Australian Children's Education and Care Quality Authority (ACECQA) awareness programs. These programs are vital in educating educators, caregivers, and healthcare providers about the early detection and management of allergies, particularly anaphylaxis, in pediatric populations.
ACECQA provides evidence-based resources and training specifically designed for education and care services, helping them recognize the signs of allergies and implement effective management strategies. This growing awareness prompts more parents to seek diagnostic testing for their children at earlier stages, leading to increased demand for advanced diagnostic tools. Furthermore, governments in various countries recognize the burden of allergic diseases on public health and invest in programs to diagnose and manage these conditions early. Initiatives to improve air quality, regulate food labeling, and increase funding for allergy research are creating a favorable environment for the diagnostics market's growth.
Pediatric Allergy Diagnostics Market Report Highlights
Pediatric Allergy Diagnostics Market Growth & Trends
The global pediatric allergy diagnostics market is anticipated to reach USD 4.68 billion by 2030 and is projected to grow at a CAGR of 10.1% during the forecast period, according to a new report by Grand View Research, Inc., driven by the increasing prevalence of allergic conditions among children worldwide. Allergies, including asthma, rhinitis, and food allergies, have become a major public health concern, especially in developed countries. A report published by the World Allergy Organization Journal in October 2023 highlighted that the lifetime prevalence rate of rhinitis symptoms in children was 18.7%. In addition, 14.3% of children experienced rhinitis symptoms within the past 12 months.
Furthermore, 5.6% of children reported having current symptoms of rhinoconjunctivitis. The rising incidence is largely attributed to environmental changes, dietary shifts, and increased awareness of allergic conditions. As a result, the demand for accurate and early diagnosis has surged, expanding the market. This market encompasses various diagnostic tools and tests, such as skin prick tests, specific IgE tests, and in vitro assays, which are crucial for identifying allergic triggers in children. The market's growth is further fueled by advancements in diagnostic technologies, improving the accuracy and ease of allergy testing, making it a pivotal segment in pediatric healthcare.
Technological advancements in diagnostic tools are a crucial factor driving the market's growth. Traditional methods, such as skin prick tests and specific IgE blood tests, have been the standard for diagnosing allergies. However, these methods can be uncomfortable for children and may not always provide the most accurate results. The market is shifting towards more sophisticated technologies, including molecular diagnostics and multiplex assays. These innovations offer higher sensitivity and specificity, allowing for the detection of multiple allergens simultaneously from a single sample. Moreover, advancements in non-invasive testing methods, such as saliva-based diagnostics, make the testing process more child-friendly, encouraging widespread adoption in pediatric settings. As these technologies continue to evolve, they are expected to drive significant growth in the market by improving diagnostic accuracy and patient compliance.
In addition, with the rising prevalence of allergic conditions such as asthma, food allergies, and atopic dermatitis in children, there is a heightened focus on early diagnosis and management. Awareness campaigns led by healthcare organizations, schools, and governments are educating parents and caregivers about the signs and symptoms of allergies, the importance of early detection, and the potential long-term impacts of untreated allergies. One such initiative is the Australian Children's Education and Care Quality Authority (ACECQA) awareness programs. These programs are vital in educating educators, caregivers, and healthcare providers about the early detection and management of allergies, particularly anaphylaxis, in pediatric populations.
ACECQA provides evidence-based resources and training specifically designed for education and care services, helping them recognize the signs of allergies and implement effective management strategies. This growing awareness prompts more parents to seek diagnostic testing for their children at earlier stages, leading to increased demand for advanced diagnostic tools. Furthermore, governments in various countries recognize the burden of allergic diseases on public health and invest in programs to diagnose and manage these conditions early. Initiatives to improve air quality, regulate food labeling, and increase funding for allergy research are creating a favorable environment for the diagnostics market's growth.
Pediatric Allergy Diagnostics Market Report Highlights
- The consumables segment held the largest share of 62.95% in 2023 and is expected to grow at the fastest CAGR over the forecast period, driven by increasing demand for allergy testing and management solutions. Key players like Thermo Fisher Scientific, Siemens Healthineers, and Abbott are leading the development of innovative diagnostic consumables, including test kits, reagents, and sample collection tools
- The inhaled segments held the largest share of 45.40% in 2023 due to increasing awareness of respiratory allergies and advancements in inhaled diagnostic technologies. Products, like inhaled allergen challenge tests, are becoming more prevalent, helping to accurately diagnose conditions such as asthma and allergic rhinitis in children
- The in vitro test segment held the largest share of 51.76% in 2023 and is expected to grow at the fastest CAGR over the forecast period, driven by advances in diagnostic technology and increased demand for precise allergy testing
- The North American market dominated the overall global market and accounted for a 36.44% revenue share in 2023, driven by the rising incidence of allergies and supportive government initiatives
- The competitive scenario in the pediatric cardiac tumor diagnostic market is high, with key players holding significant positions. The major companies are undertaking various strategies, such as collaborations, new product development, mergers, acquisitions, and geographic expansion, to serve their customers' unmet needs
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Biomarker
1.2.3. End use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Indication outlook
2.2.2. Biomarker outlook
2.2.3. End use outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PEDIATRIC CANCER BIOMARKERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Pediatric Cancer
3.2.1.2. Growing Awareness and Government Initiatives
3.2.1.3. Advancements in Genomics and Proteomics
3.2.2. Market Restraint Analysis
3.2.2.1. High Costs of Research and Development
3.2.2.2. Complex Regulatory Requirements
3.3. Pediatric Cancer Biomarkers Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PEDIATRIC CANCER BIOMARKERS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Pediatric Cancer Biomarkers Market: Indication Movement Analysis
4.3. Pediatric Cancer Biomarkers Market by Indication Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Leukemia
4.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Neuroblastoma
4.6.1. Neuroblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. CNS Tumors
4.7.1. CNS Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Lymphoma
4.8.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Others
4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PEDIATRIC CANCER BIOMARKERS MARKET: BIOMARKER ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Pediatric Cancer Biomarkers Market: Biomarker Movement Analysis
5.3. Pediatric Cancer Biomarkers Market by Biomarker Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Alpha-fetoprotein (AFP)
5.5.1. Alpha-fetoprotein (AFP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Neuron-specific enolase (NSE)
5.6.1. Neuron-specific enolase (NSE) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. CD19, CD20, CD22
5.7.1. CD19, CD20, CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. ALK (anaplastic lymphoma receptor tyrosine kinase gene)
5.8.1. ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PEDIATRIC CANCER BIOMARKERS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Pediatric Cancer Biomarkers Market: End Use Movement Analysis
6.3. Pediatric Cancer Biomarkers Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospital
6.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Oncology Centers
6.7.1. Oncology Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Research Institutions
6.8.1. Research Institutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PEDIATRIC CANCER BIOMARKERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Strategy Mapping
8.4. Key Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Abbott
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Siemens Healthineers
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. QIAGEN
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Myriad Genetics
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Beckman Coulter
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Bio-Rad Laboratories
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Agilent Technologies
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BIOMЙRIEUX
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. RayBiotech, Inc
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Randox Laboratories Ltd.
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Biomarker
1.2.3. End use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Indication outlook
2.2.2. Biomarker outlook
2.2.3. End use outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PEDIATRIC CANCER BIOMARKERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Pediatric Cancer
3.2.1.2. Growing Awareness and Government Initiatives
3.2.1.3. Advancements in Genomics and Proteomics
3.2.2. Market Restraint Analysis
3.2.2.1. High Costs of Research and Development
3.2.2.2. Complex Regulatory Requirements
3.3. Pediatric Cancer Biomarkers Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PEDIATRIC CANCER BIOMARKERS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Pediatric Cancer Biomarkers Market: Indication Movement Analysis
4.3. Pediatric Cancer Biomarkers Market by Indication Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Leukemia
4.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Neuroblastoma
4.6.1. Neuroblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. CNS Tumors
4.7.1. CNS Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Lymphoma
4.8.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Others
4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PEDIATRIC CANCER BIOMARKERS MARKET: BIOMARKER ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Pediatric Cancer Biomarkers Market: Biomarker Movement Analysis
5.3. Pediatric Cancer Biomarkers Market by Biomarker Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Alpha-fetoprotein (AFP)
5.5.1. Alpha-fetoprotein (AFP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Neuron-specific enolase (NSE)
5.6.1. Neuron-specific enolase (NSE) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. CD19, CD20, CD22
5.7.1. CD19, CD20, CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. ALK (anaplastic lymphoma receptor tyrosine kinase gene)
5.8.1. ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PEDIATRIC CANCER BIOMARKERS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Pediatric Cancer Biomarkers Market: End Use Movement Analysis
6.3. Pediatric Cancer Biomarkers Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospital
6.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Oncology Centers
6.7.1. Oncology Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Research Institutions
6.8.1. Research Institutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PEDIATRIC CANCER BIOMARKERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Strategy Mapping
8.4. Key Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Abbott
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Siemens Healthineers
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. QIAGEN
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Myriad Genetics
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Beckman Coulter
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Bio-Rad Laboratories
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Agilent Technologies
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BIOMЙRIEUX
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. RayBiotech, Inc
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Randox Laboratories Ltd.
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
